No internet connection — showing the saved version of the page.

Illumina Inc

USUSD
← to the screener
US:ILMNLSE:0J8Z

Illumina Inc (US:ILMN) — Medical Specialities. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
illumina.com
Investor relations
investor.illumina.com/investors/default.aspx
Sector
Health Care · Medical Specialities
Headquarters
San Diego, United States
Management
Jacob Thaysen
  • Jacob Thaysen · Chief Executive Officer
  • Caroline Dorsa · Scott Gottlieb, MD, Chair
  • Scott Gottlieb · MD, Chair
  • Ankur Dhingra · Chief Financial Officer
  • Coronavirus Characterization · IDbyDNA Partnership on NGS Infectious Disease Solutions
  • Mark Field · Chief Information Officer
  • Rami Mehio · Senior Vice President, General Manager, BioInsight
  • Jakob Wedel · Chief Strategy and Corporate Development Officer
  • Pat Leckman · Chief People Officer
  • Kevin Pegels · Chief of Global Operations
Employees
9 250
Founded
1998
IPO
2000-06-28
Shares outstanding
151.2 M as of 2026-10-23
DateSharesChange
23.10.2026151.2 M+0.1%issuance (dilution)
24.07.2026151 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
149.78 M
Market cap
43.8 B USD
Insiders
0.21%
Institutions
106.47%
Industry (SIC)
Laboratory Analytical Instruments
Legal form
XTIQ
ISIN
US4523271090
LEI
SQ95QG8SR5Q56LSNF682
P/E
34.5
EPS
5.81 USD
|
9.65
Graham number
35.65 USD price 463% above
ROE
32.5%
Payout ratio
0%
FCF
1.06 B USD
Debt
1.79 B USD
1.7 y of FCF
Earnings, FCF and dividends paid — for the 12 months to 27.09.2026 (the company's latest report).
Net income
895 M USD 12 mo.
For the 12 months to 27.09.2026 (4 quarters)
Revenue4.54 B USD
− Expenses3.58 B USD
Gross profit3.08 B USD
Net income895 M USD
History by quarter
RevenueExpensesLoss
31.12.2023: Revenue 1.12 B · Expenses 1.29 B · Operating profit −164 M · Net income −175 M31.03.2024: Revenue 1.08 B · Expenses 1.19 B · Operating profit −111 M · Net income −126 M30.06.2024: Revenue 1.11 B · Expenses 2.75 B · Operating profit −1.64 B · Net income −1.99 B29.09.2024: Revenue 1.08 B · Expenses 339 M · Operating profit 741 M · Net income 705 M29.12.2024: Revenue 1.10 B · Expenses 929 M · Operating profit 175 M · Net income 187 M30.03.2025: Revenue 1.04 B · Expenses 877 M · Operating profit 164 M · Net income 131 M29.06.2025: Revenue 1.06 B · Expenses 845 M · Operating profit 214 M · Net income 235 M28.09.2025: Revenue 1.08 B · Expenses 857 M · Operating profit 227 M · Net income 150 M28.12.2025: Revenue 1.16 B · Expenses 958 M · Operating profit 201 M · Net income 334 M29.03.2026: Revenue 1.09 B · Expenses 882 M · Operating profit 209 M · Net income 134 M28.06.2026: Revenue 1.16 B · Expenses 914 M · Operating profit 245 M · Net income 207 M27.09.2026: Revenue 1.13 B · Expenses 824 M · Operating profit 305 M · Net income 220 M
12.202309.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
20.80 USD · P/NAV 9.65
Balance sheet date27.09.2026
Assets6.81 B USD
− Liabilities3.67 B USD
= NAV (equity of the company's shareholders)3.15 B USD
− Goodwill1.28 B USD
− Intangible assets391 M USD
= Tangible NAV1.47 B USD
Shares151 200 000
NAV per share20.80 USD
Tangible NAV per share9.72 USD
Share price (ILMN)200.66 USD
P/NAV9.65
NAV history
Balance sheet dateNAVNAV per share
27.09.20263.15 B USD20.80 USD
28.06.20262.84 B USD18.79 USD
29.03.20262.68 B USD17.69 USD
28.12.20252.72 B USD17.80 USD
28.09.20252.38 B USD15.58 USD
29.06.20252.26 B USD14.69 USD
30.03.20252.37 B USD14.96 USD
29.12.20242.37 B USD14.92 USD
Description

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
US USA StocksILMN primaryUSD200.655 -4.45%common stock
LSE London Stock Exchange0J8Z IOBUSD198.28 -4.34%common stock
depositary receipt
SA B3 Sao PauloI1LM34BRL—depositary receipt

Price

Hover / tap a day — open, close, high and low prices

Dividends

Ex-datePaymentAmount%TypeTicker
2024-06-25—3.1051 USD1.6/1.6 %—LSE:0J8Z

News this week

Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.

Top holders

HolderStakeSharesReport date
Blackrock Inc.12.71%19.19 M2026-06-30
Capital World Investors10.22%15.43 M2026-06-30
Vanguard Portfolio Manag…4.39%6.63 M2026-06-30
Vanguard Capital Managem…4.36%6.59 M2026-06-30
State Street Corporation4.31%6.51 M2026-06-30
WCM Investment Managemen…4.11%6.21 M2026-06-30
iShares Trust-iShares Co…3.51%5.3 M2026-08-31
VANGUARD INDEX FUNDS-Van…3.02%4.56 M2026-06-30
FMR, LLC3%4.52 M2026-06-30
AQR Capital Management,…2.35%3.54 M2026-06-30
Primecap Management Comp…2.33%3.51 M2026-06-30
AMERICAN BALANCED FUND2.31%3.49 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.3 M2026-06-30
Geode Capital Management…1.95%2.95 M2026-06-30
Growth Fund of America1.82%2.74 M2026-06-30
New Economy Fund1.78%2.68 M2026-06-30
VANGUARD HORIZON FUNDS-V…1.17%1.76 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.74 M2026-06-30
WASHINGTON MUTUAL INVEST…1.04%1.57 M2026-07-31
NEW PERSPECTIVE FUND0.93%1.4 M2026-06-30
THAYSEN JACOB (Chief Exe…≈0.07%109 0732026-03-05
CUNNINGHAM EVERETT V (Of…≈0.03%50 8402025-03-05
BARNARD STEVEN (Chief Te…≈0.03%41 3352026-03-05
DHINGRA ANKUR (Chief Fin…≈0.02%34 2642026-03-05
PEGELS KEVIN CARL (Offic…≈0.02%29 0382026-03-05
SCHILLER PHILIP W (Direc…≈0.01%22 2202026-05-21
EPSTEIN ROBERT S (Direct…≈0.01%22 1392025-05-21
LECKMAN PATRICIA L (Offi…≈0.01%21 2592026-06-05
ARNOLD FRANCES H PH.D. (…≈0.01%20 9072025-05-21
MEISTER KEITH A (Directo…——2026-09-04